Ardent Health, Inc. insider trading
Every open-market purchase and sale by Ardent Health, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Ardent Health, Inc.’s insiders pay?
From November 13, 2024 to June 8, 2026, 3 insiders reported 3 open-market purchases and 0 sales not made under a pre-set plan in Ardent Health, Inc. Twelve months after each purchase was reported, the shares were −63.8% against the S&P 500 on average (median −63.8%), over 1 purchase with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 14, 2024 into $6,438 by November 2, 2026, −20.2% a year. It held shares 71% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $12,070 (+10.1% a year), and held throughout $13,044 (+14.6%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Demichiei Robert | Director | 1 | — | — | 0 | — | June 8, 2026 |
| Lumsdaine Alfred | Chief Financial Officer | 1 | — | — | 0 | — | June 8, 2026 |
| Webb Robert Thomas | Director | 1 | −63.8% (1) | 0% | 0 | — | November 13, 2024 |
When several insiders traded Ardent Health, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Ardent Health, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| June 30, 2026 | 2 buying | +4.9% | not yet | not yet |